泛醇(还原型辅酶Q10)作为心脏骤停后代谢复苏剂:一项随机、双盲、安慰剂对照试验
主要终点24小时血浆总辅酶Q10水平在泛醇组显著高于安慰剂组(441 vs 113 ηg/mL,P<0.001)。但神经元特异性烯醇化酶、S100B、乳酸、细胞及整体氧耗、神经功能状态及院内死亡率等次要终点均无差异。提示泛醇虽可提升辅酶Q10水平,但未转化为代谢或神经保护获益。
要点
- 心脏骤停复苏后患者肠内泛醇300 mg每12小时一次,24小时血浆辅酶Q10水平显著高于安慰剂(441 vs 113 ηg/mL,P<0.001)。
- 泛醇组与安慰剂组24小时神经元特异性烯醇化酶无差异(16.8 vs 8.2 ηg/mL,P=0.61)。
- 两组在S100B、乳酸、细胞及整体氧耗、神经功能状态及院内死亡率等次要终点均无差异。
适用人群与场景
- 原文未提及具体纳入/排除标准、急诊/ICU/院前场景或病情阶段。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 肠内给予泛醇300 mg,每12小时一次,最长7天;或安慰剂对照。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 人群:心脏骤停成功复苏患者。
- 干预与对照:肠内泛醇300 mg每12小时一次 vs 安慰剂,最长7天。
- 主要终点:24小时血浆总辅酶Q10水平,泛醇组显著高于安慰剂组(441 [IQR 215-510] ηg/mL vs 113 [IQR 94-208] ηg/mL,P<0.001);48及72小时结果类似。
- 关键次要终点:24小时神经元特异性烯醇化酶无差异(16.8 [IQR 9.5-19.8] ηg/mL vs 8.2 [IQR 4.3-19.1] ηg/mL,P=0.61);S100B、乳酸、细胞及整体氧耗、神经功能状态、院内死亡率均无差异。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照试验。
- 证据等级或推荐强度:原文未提及。
对床旁实践的改变
- 原文结果不支持将肠内泛醇300 mg每12小时一次用于心脏骤停后患者以改善氧耗或神经损伤生物标志物。
- 泛醇可提高血浆辅酶Q10水平,但未转化为临床获益,不应据此改变现有复苏后管理。
- 适用人群为心脏骤停成功复苏患者;不适用人群原文未提及。
- 常见陷阱:勿将药代动力学改善误认为临床疗效。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Ubiquinol (reduced coenzyme Q10) is essential for adequate aerobic metabolism. The objective of this trial was to determine whether ubiquinol administration in patients resuscitated from cardiac arrest could increase physiological coenzyme Q10 levels, improve oxygen consumption, and reduce neurological biomarkers of injury.
MATERIALS AND METHODS: This was a randomized, double-blind, placebo-controlled trial in patients successfully resuscitated from cardiac arrest. Patients were randomized to receive enteral ubiquinol (300 mg) or placebo every 12 h for up to 7 days. The primary endpoint was total coenzyme Q10 plasma levels at 24 h after enrollment. Secondary endpoints included neuron specific enolase, S100B, lactate, cellular and global oxygen consumption, neurological status, and in-hospital mortality.
RESULTS: Forty-three patients were included in the modified intention-to-treat analysis. Median coenzyme Q10 levels were significantly higher in the ubiquinol group as compared to the placebo group at 24 h (441 [IQR, 215-510] ηg/mL vs. 113 [IQR, 94-208] ηg/mL, P < 0.001). Similar results were observed at 48 and 72 h. There were no differences between the two groups in any of the secondary endpoints. Median neuron specific enolase levels were not different between the two groups at 24 h (16.8 [IQR, 9.5-19.8] ηg/mL vs. 8.2 [IQR, 4.3-19.1] ηg/mL, P = 0.61).
CONCLUSIONS: Administration of enteral ubiquinol increased plasma coenzyme Q10 levels in post-cardiac arrest patients as compared to placebo. There were no differences in neurological biomarkers and oxygen consumption between the two groups.
参考来源
- Holmberg MJ, Andersen LW, Moskowitz A, et al. Ubiquinol (reduced coenzyme Q10) as a metabolic resuscitator in post-cardiac arrest: A randomized, double-blind, placebo-controlled trial. Resuscitation. 2021. PMID: 33577964. doi:10.1016/j.resuscitation.2021.01.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。